Glenmark Expands U.S. Portfolio with Lacosamide

Glenmark Pharmaceuticals has announced the launch of Lacosamide Oral Solution, 10 mg/mL, a bioequivalent and therapeutically equivalent generic of Vimpat® Oral Solution by UCB, Inc. The product caters to a U.S. market valued at approximately $57 million annually as of October 2024.

Marc Kikuchi, President of Glenmark North America, emphasized the company's dedication to offering high-quality, affordable alternatives for patients. Glenmark's U.S. portfolio now includes 201 approved products, with 51 ANDAs pending FDA approval, as the company continues expanding through both internal development and external partnerships.